Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

Journal of Dermatology

Volumn 37, Issue 5, 2010, Pages 413-425

  Reddy, Manjula ^a   Torres, Gisela ^a   McCormick, Thomas ^a   Marano, Colleen ^a   Cooper, Kevin ^a   Yeilding, Newman ^a   Wang, Yuhua ^a   Pendley, Charles ^b   Prabhakar, Uma ^a,d   Wong, Jackson ^a   Davis, Cuc ^a   Xu, Stephen ^a   Brodmerkel, Carrie ^c  

^a CENTOCOR INC   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Frontage Laboratories   (United States)

Author keywords

Interleukin 12; Interleukin 23; Psoriasis; T cells; Ustekinumab

Indexed keywords

BIOLOGICAL MARKER; CD3 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CYTOKINE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23; INTERLEUKIN 8; KI 67 ANTIGEN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB; KERATOLYTIC AGENT; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; CELL SURFACE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EX VIVO STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PROTEIN BLOOD LEVEL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN BIOPSY; SKIN DEFECT; SKINFOLD THICKNESS; TH1 CELL; TH2 CELL; CELL PROLIFERATION; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MALE; MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL PROLIFERATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; KERATOLYTIC AGENTS; LEUKOCYTES, MONONUCLEAR; MALE; PSORIASIS; SEVERITY OF ILLNESS INDEX; TH1 CELLS; TH2 CELLS; TREATMENT OUTCOME;

EID: 77951838972     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.00802.x     Document Type: Article

References (35)

1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007 445 : 866 873.
2. Lowes MA, Kikuchi T, Fuentes-Duculan J et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008 128 : 1207 1211.
3. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009 129 : 79 88.
4. Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U. Modulation of CLA, IL-12R, CD40L, and IL-2R alpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol 2007 247 : 1 11.
5. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003 3 : 133 146.
6. Rogge L, Barberis-Maino L, Biffi M et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 1997 185 : 825 831.
7. Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007 8 : 950 957.
8. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005 201 : 233 240.
9. Barrie AM III, Plevy SE. The interleukin-12 family of cytokines: therapeutic targets for inflammatory disease mediation. Clin Appl Immunol Rev 2005 5 : 225 240.
10. Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol 1999 162 : 7480 7491.
11. Chan JR, Blumenschein W, Murphy E et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006 203 : 2577 2587.
12. Zheng Y, Danilenko DM, Valdez P et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007 445 : 648 651.
13. Roussaki-Schulze AV, Kouskoukis C, Petinaki E et al. Evaluation of cytokine serum levels in patients with plaque-type psoriasis. Int J Clin Pharmacol Res 2005 25 : 169 173.
14. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006 176 : 1908 1915.
15. Lee E, Trepicchio WL, Oestreicher JL et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004 199 : 125 130.
16. Toichi E, Torres G, McCormick TS et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006 177 : 4917 4926.
17. Kauffman CL, Aria N, Toichi E et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004 123 : 1037 1044.
18. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009 373 : 633 640.
19. Krueger GG, Langley RG, Leonardi C et al. for the CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007 356 : 580 592.
20. Leonardi CL, Kimball AB, Papp KA et al. for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 371 : 1665 1674.
21. Papp KA, Langley RG, Lebwohl M et al. for the PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 371 : 1675 1684.
22. Looney RJ, Diamond B, Holers VM et al. for the Autoimmunity Centers of Excellence Immunocompetency Committee. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin Immunol 2007 123 : 235 243.
23. Czerkinsky C, Andersson G, Ekre HP, Nilsson LA, Klareskog L, Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods 1988 110 : 29 36.
24. Bennouna J, Hildesheim A, Chikamatsu K, Gooding W, Storkus WJ, Whiteside TL. Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses. J Immunol Methods 2002 261 : 145 156.
25. Kreher CR, Dittrich MT, Guerkov R, Boehm BO, Tary-Lehmann M. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods 2003 278 : 79 93.
26. Gottlieb AB, Chamian F, Masud S et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005 175 : 2721 2729.
27. Reddy M, Wong J, Pendley C, Prabhakar U. IFN-γ ELISPOT assay validation. In : Prabhakar U, Kelley M eds. Validation of Cell-Based Assays in the GLP Setting, A Practical Guide, 1st edn.
28. Reddy M, Wong J, Davis H, Pendley C, Prabhakar U. IL-5 ELISPOT assay validation. In : Prabhakar U, Kelley M eds. Validation of Cell-Based Assays in the GLP Setting, A Practical Guide, 1st edn.
29. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008 128 : 1064 1067.
30. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003 278 : 1910 1914.
31. Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Investig Dermatol Symp Proc 2007 12 : 9 15.
32. Reich K, Nestle FO, Papp K et al. for the EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 366 : 1367 1374.
33. Chamian F, Lowes MA, Lin SL et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 2005 102 : 2075 2080.
34. Lebwohl M, Tyring SK, Hamilton TK et al. for the Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003 349 : 2004 2013.
35. Lowes MA, Chamian F, Abello MV et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005 102 : 19057 19062.